Nykode Therapeutics AS
Oslo Stock Exchange NYKD.OL
Nykode Therapeutics AS EBIT for the year ending December 31, 2023: USD -43.86 M
-
Nykode Therapeutics AS EBIT for the year ending December 31, 2022 was USD -50.74 M, a -361.84% change year over year.
-
Nykode Therapeutics AS EBIT for the year ending December 31, 2021 was USD -10.99 M, a -106.07% change year over year.
-
Nykode Therapeutics AS EBIT for the year ending December 31, 2020 was USD 180.95 M, a 247.85% change year over year.
-
Nykode Therapeutics AS EBIT for the year ending December 31, 2019 was USD -122.39 M, a -85.90% change year over year.
| Date | EBIT | EBITDA | Net Income | EPS (Diluted) |
|---|
| CEO | Mr. Michael Thyring Engsig |
| IPO Date | Oct. 7, 2020 |
| Location | Norway |
| Headquarters | Oslo Research Park |
| Employees | 179 |
| Sector | Health Care |
| Industries | |
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for COVID-19 T cell vaccine development; and research agreement with Regeneron. The company was formerly known as Vaccibody AS. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email